Budesonide MMX®

DRUG3 trials

Sponsors

Bausch Health Americas, Inc., Ferring Pharmaceuticals, University of Calgary

Conditions

Microscopic ColitisUlcerative Colitis

Phase 2

Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis

Not yet recruitingNCT05915104

University of CalgaryMicroscopic Colitis

Start: 2024-01-01End: 2026-12-31Target: 80Updated: 2023-12-04

Phase 3

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

CompletedNCT01532648

Bausch Health Americas, Inc.Ulcerative Colitis

Start: 2012-01-27End: 2013-10-02Updated: 2019-09-06

Unknown Phase

Effectiveness of Cortiment® in Patients With Ulcerative Colitis

CompletedNCT02586259

Ferring PharmaceuticalsUlcerative Colitis

Start: 2015-12-31End: 2018-04-05Updated: 2019-11-20

Related Papers

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study

BMJ Open Gastroenterology2016-05-0112 citations